title: [Heart failure in chronic kidney disease: from epidemiology to therapy].
abstract: Many patients affected by chronic kidney disease (CKD) die before reaching endstage renal disease because of cardiovascular disease (CVD). Recent guidelines and position statements have therefore defined CKD as a cardiovascular risk equivalent, and patients in all stages of CKD are considered in the highest risk group for development of CVD. Heart failure (HF) is the main cardiovascular complication that occurs in renal patients and its incidence increases proportionally with the reduction of glomerular filtration rate. In fact, pressure and volume overload, that are inherent to the abnormalities of homeostasis typical of CKD, lead to concentric/eccentric left ventricular hypertrophy (LVH). Initially, LVH is adaptative because energy is spared by maintaining stable wall stress. However, in the long term, LVH becomes maladaptative, inducing systolic and/or diastolic dysfunction that, in turn, lead to symptomatic left ventricular failure. Nowadays, it is well established that several classes of drugs, including reninangiotensin system antagonists, beta blockers and aldosterone antagonists, improve survival in patients with HF. In fact, all major guidelines on HF recommend such drugs as standard therapy. The problem for nephrologists is that the general approach and recommendations for the management of HF in the general population may not be completely safe in renal patients with HF. This review is conducted with the purpose to provide more information on the efficacy and safety of HF therapy in renal patients.
authors.affiliation: Cattedra di Nefrologia, II Università degli Studi, Napoli, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Zamboli
authors.forename: L
authors.initials: L
authors.lastname: De Nicola
authors.forename: R
authors.initials: R
authors.lastname: Minutolo
authors.forename: G
authors.initials: G
authors.lastname: Stanzione
authors.forename: V
authors.initials: V
authors.lastname: Bertino
authors.forename: R
authors.initials: R
authors.lastname: Sosio
authors.forename: A
authors.initials: A
authors.lastname: De Luca
authors.forename: M
authors.initials: M
authors.lastname: Crivaro
authors.forename: S
authors.initials: S
authors.lastname: Tassinario
authors.forename: G
authors.initials: G
authors.lastname: Conte
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000453:epidemiology; D000451:Mineralocorticoid Receptor Antagonists
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists